Please login to the form below

Not currently logged in
Email:
Password:

Takeda will acquire Nycomed, reports say

Takeda Pharmaceutical Company has agreed to buy Swiss drugmaker Nycomed in a deal worth around 1trn yen ($12bn), according to a report in Japanese newspaper, Nikkei

Takeda Pharmaceutical Company has agreed to buy Swiss drugmaker Nycomed in a deal worth around 1trn yen ($12bn), according to a report in Japanese newspaper, Nikkei.

The report follows denials by Takeda, the largest pharma company in Japan, earlier this month: "Takeda has not agreed to any such agreement as suggested by certain newspaper publications… Takeda is constantly seeking and evaluating opportunities to increase shareholder value and enhance our business through strategic investment, however, there is nothing that needs to be announced at this point."

Initial media reports had alleged that the deal was in its final stages, while another said that Takeda is talking to banks about financing the deal.

Rumours of the deal came just days after Nycomed entered into a co-branding agreement with Almirall to commercialise roflumilast in Spain. Romflumilast is a once-daily tablet for patients with COPD. It is an orally administered phosphodiesterase 4 (PED4) enzyme inhibitor and the first oral anti-inflammatory treatment for COPD.

Related stories
Takeda denies Nycomed takeover talks
Almirall/Nycomed COPD co-branding deal

18th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics